Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Rua Bioscience Limited Capital/Financing Update 2024

Oct 30, 2024

66262_rns_2024-10-31_092ed71f-6f34-4709-be3a-3d0de098b2c1.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

MARKET UPDATE

==> picture [132 x 77] intentionally omitted <==

FOR PUBLIC RELEASE NZX Limited Wellington

31[st] October 2024

Update: Unconditional sales contract of Rua manufacturing facility

At the time of this release Rua Bioscience has not received the settlement funds from the the purchaser, Awa Ora Genesis Kaitiaki Harakeke Trust of Te Araroa, for the purchase of the Gisborne manufacturing facility.

The contract is for $1.3 mill and was due to be paid in full by 5pm yesterday, 30th October 2024.

The Board have received assurances from the Trust that they intend to complete the purchase of the property and have requetsed further time before settlement.

The Board is now considering their legal options in this situation and are also in parallel working with other credible parties on an alternate purchase plan.

The Board will update the market as soon as new information is received.

ENDS

The person who authorised this announcement:

Paul Naske Chief Executive Officer [email protected] +64 21 445154

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com